{"id":359767,"date":"2026-04-02T17:33:04","date_gmt":"2026-04-02T12:03:04","guid":{"rendered":"https:\/\/forumias.com\/blog\/?p=359767"},"modified":"2026-04-02T17:33:04","modified_gmt":"2026-04-02T12:03:04","slug":"tak-003-dengue-vaccine","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/tak-003-dengue-vaccine\/","title":{"rendered":"TAK-003 Dengue Vaccine"},"content":{"rendered":"<p><strong>News: <\/strong>TAK-003 dengue vaccine received clearance from Subject Expert Committee under Drugs Controller General of India for individuals aged 4 to 60 years.<\/p>\n<h2>About TAK-003 Dengue Vaccine<\/h2>\n<figure id=\"attachment_359768\" aria-describedby=\"caption-attachment-359768\" style=\"width: 432px\" class=\"wp-caption aligncenter\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\" wp-image-359768\" src=\"https:\/\/i0.wp.com\/forumias.com\/blog\/wp-content\/uploads\/2026\/04\/Source-NDTV.jpg?resize=432%2C245&#038;ssl=1\" alt=\"TAK-003 Dengue Vaccine\" width=\"432\" height=\"245\" srcset=\"https:\/\/i0.wp.com\/forumias.com\/blog\/wp-content\/uploads\/2026\/04\/Source-NDTV.jpg?resize=300%2C170&amp;ssl=1 300w, https:\/\/i0.wp.com\/forumias.com\/blog\/wp-content\/uploads\/2026\/04\/Source-NDTV.jpg?w=578&amp;ssl=1 578w\" sizes=\"auto, (max-width: 432px) 100vw, 432px\" \/><figcaption id=\"caption-attachment-359768\" class=\"wp-caption-text\">Source &#8211; NDTV<\/figcaption><\/figure>\n<ul>\n<li>TAK-003 (commonly known as &#8216;<strong>Qdenga<\/strong>&#8216;) is a<strong> tetravalent dengue vaccine<\/strong> designed to protect against <strong>all four <\/strong><strong>dengue virus <\/strong>serotypes 1, 2, 3, and 4.<\/li>\n<li><strong>Developed by:<\/strong> The vaccine is <strong>developed by Takeda.<\/strong><\/li>\n<li><strong>Mechanism:<\/strong> It is a <strong>live-attenuated vaccine<\/strong> containing <strong>weakened versions of dengue virus <\/strong>serotypes 1, 2, 3, and 4, and it <strong>uses the DENV-2 strain<\/strong> as the <strong>genomic backbone<\/strong>.<\/li>\n<li><strong>Dose<\/strong><strong>:<\/strong> The vaccine is administered as a <strong>two-dose series<\/strong>, with both doses given <strong>three months apart<\/strong>.<\/li>\n<li><strong>Eligibility:<\/strong> It has received <strong>clearance<\/strong> for use among individuals <strong>aged 4 to 60 years in India.<\/strong>\n<ul>\n<li><strong>WHO Recommendation:<\/strong> As per WHO guidance, TAK-003 (Qdenga) is recommended for <strong>children aged 6 to 16 years<\/strong> in settings with high dengue transmission, and it is administered as a <strong>two-dose series<\/strong> with a three-month interval.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Strong protection:<\/strong> The vaccine provides strong protection against severe dengue and hospitalisation, reducing pressure on healthcare systems.<\/li>\n<li><strong>Nature of protection:<\/strong> It reduces severity of illness rather than completely preventing infection, so dengue transmission may continue.<\/li>\n<li><strong>Limitation:<\/strong> It shows <strong>lower effectiveness against DENV-3 and DENV-4,<\/strong> especially in individuals without prior infection.<\/li>\n<li><strong>India-specific Context:<\/strong> All <strong>four serotypes co-circulate<\/strong> in India, with <strong>DENV-2<\/strong> accounting for <strong>about 48\u201366% cases<\/strong> and <strong>DENV-3 contributing<\/strong> around 20\u201330%, indicating evolving epidemiology.<\/li>\n<\/ul>\n<h2>About India\u2019s Dengue Vaccine Pipeline<\/h2>\n<ul>\n<li><strong>Indigenous candidate:<\/strong> <strong>\u2018DengiAll\u2019<\/strong> is being developed by <strong>Panacea Biotec<\/strong> in collaboration with <strong>Indian Council of Medical Research (ICMR)<\/strong>.<\/li>\n<li><strong>Clinical stage:<\/strong> It is currently undergoing <strong>large phase III clinical trials<\/strong>, indicating advanced evaluation status.<\/li>\n<li><strong>Scientific basis:<\/strong> The vaccine is based on the National Institutes of Health\u00a0(NIH) <strong>TV003 platform<\/strong> and is designed as a <strong>single-dose vaccine<\/strong> for <strong>balanced protection across all four serotypes<\/strong>.<\/li>\n<li><strong>Future potential:<\/strong> If successful, it may be <strong>available around 2027<\/strong> and could offer <strong>broader protection and better suitability<\/strong> for large-scale public health deployment.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>News: TAK-003 dengue vaccine received clearance from Subject Expert Committee under Drugs Controller General of India for individuals aged 4 to 60 years. About TAK-003 Dengue Vaccine TAK-003 (commonly known as &#8216;Qdenga&#8216;) is a tetravalent dengue vaccine designed to protect against all four dengue virus serotypes 1, 2, 3, and 4. Developed by: The vaccine&hellip; <a class=\"more-link\" href=\"https:\/\/forumias.com\/blog\/tak-003-dengue-vaccine\/\">Continue reading <span class=\"screen-reader-text\">TAK-003 Dengue Vaccine<\/span><\/a><\/p>\n","protected":false},"author":10393,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[1566,956,1738,12039],"tags":[11872],"class_list":["post-359767","post","type-post","status-publish","format-standard","hentry","category-daily-factly-articles","category-schemes-and-programs","category-science-and-technology-daily-factly-articles","category-knolls","tag-9pm-daily-factly","entry"],"jetpack_featured_media_url":"","views":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/359767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10393"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=359767"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/359767\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=359767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=359767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=359767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}